Sektor-News

EQS-News: Abivax Announces Positive Phase 3 Results from Both ABTECT 8-Week Induction Trials Investigating Obefazimod, its First-in-Class Oral miR-124 Enhancer, in Moderate to Severely Active Ulcerati

EQS-News: ABIVAX / Key word(s): Study results/Study Abivax Announces Positive Phase 3 Results from Both ABTECT 8-Week Induction Trials Investigating Obefazimod, its First-in-Class ...weiterlesen

Seite: 1 | 2 | 3 | 4 | 5 | 6 | ... | 100 ►

Jetzt neu: